Literature DB >> 10147036

Economic evaluation of drugs: a UK pharmaceutical industry perspective.

N Wells1.   

Abstract

Mesh：

Year:  1992        PMID： 10147036     DOI： 10.2165/00019053-199201010-00005

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  5 in total

1.  Principles of pharmacoeconomic analysis of drug therapy.

Authors:  D A Freund; R S Dittus
Journal:  Pharmacoeconomics       Date:  1992-01       Impact factor: 4.981

2.  The promise of a reformed NHS: an economist's angle.

Authors:  A J Culyer
Journal:  BMJ       Date:  1991-05-25

3.  Where is the wisdom...?

Authors:  R Smith
Journal:  BMJ       Date:  1991-10-05

4.  Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies.

Authors:  A L Hillman; J M Eisenberg; M V Pauly; B S Bloom; H Glick; B Kinosian; J S Schwartz
Journal:  N Engl J Med       Date:  1991-05-09       Impact factor: 91.245

5.  Why doctors must grapple with health economics.

Authors:  J L Appleby
Journal:  Br Med J (Clin Res Ed)       Date:  1987-02-07
  5 in total
  5 in total

1.  Interpreting economic evaluations of medicines: a new role for the pharmacist? .

Authors:  A T Denby; N E Wells
Journal:  Pharmacoeconomics       Date:  1992-08       Impact factor: 4.981

Review 2.  Economic evaluation of pharmaceuticals: a European perspective.

Authors:  M Drummond; F Rutten; A Brenna; C G Pinto; B Horisberger; B Jönsson; C Le Pen; J Rovira; M G von der Schulenburg; H Sintonen
Journal:  Pharmacoeconomics       Date:  1993-09       Impact factor: 4.981

3.  Health economics in primary care in the UK: containment of drug costs.

Authors:  T Walley; R T Edwards
Journal:  Pharmacoeconomics       Date:  1993-02       Impact factor: 4.981

4.  Guidelines for pharmacoeconomic studies. The ways forward.

Authors:  M F Drummond
Journal:  Pharmacoeconomics       Date:  1994-12       Impact factor: 4.981

Review 5.  Drug therapies for sexually transmitted diseases. Clinical and economic considerations.

Authors:  W R Bowie
Journal:  Drugs       Date:  1995-04       Impact factor: 9.546
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.